Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics develops cell therapies for autoimmune diseases, with a focus on CD19-targeting CAR T approaches. The company's recurring news centers on miv-cel, also known as mivocabtagene autoleucel or KYV-101, an autologous CAR T-cell therapy candidate being studied across B-cell-driven autoimmune diseases.
Company updates commonly cover clinical data from the KYSA neuroimmunology program, including stiff person syndrome and generalized myasthenia gravis, as well as additional autoimmune indications such as multiple sclerosis and rheumatoid arthritis. Kyverna also reports business and financial results, medical-meeting presentations, board and executive appointments, and commercial leadership developments tied to its transition from clinical development toward potential product launch activity.
Kyverna Therapeutics (Nasdaq: KYTX) reported its Q1 2024 financial results, highlighting progress in autoimmune disease therapies. The company treated 30 patients by May 14, 2024, including those with myasthenia gravis, lupus nephritis, and multiple sclerosis. KYV-101, their CD19 CAR T-cell therapy, showed promising early clinical data and received Orphan Drug Designation for myasthenia gravis. Kyverna's balance sheet was strengthened by $366.9 million from their February IPO. However, the company reported a net loss of $26.7 million for Q1 2024, up from a $11.1 million loss in Q1 2023, with operating expenses increasing significantly.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.